American Association for Cancer Research
00085472can171754-sup-184746_2_supp_4239704_xvfvvr.png (4.8 MB)

Figure S1 from KDM4 Inhibition Targets Breast Cancer Stem–like Cells

Download (4.8 MB)
posted on 2023-03-31, 01:46 authored by Eric Metzger, Stella S. Stepputtis, Juliane Strietz, Bogdan-Tiberius Preca, Sylvia Urban, Dominica Willmann, Anita Allen, Fides Zenk, Nicola Iovino, Peter Bronsert, Amelie Proske, Marie Follo, Melanie Boerries, Elmar Stickeler, Jiangchun Xu, Michael B. Wallace, Jeffrey A. Stafford, Toufike Kanouni, Jochen Maurer, Roland Schüle

Characterization of the breast cancer stem cell line BCSC2 in vitro and in vivo. Like BCSC1 in Figure 1, BCSC2-derived xenografts also recapitulate the original patient tumor.


European Research Council

Deutsche Forschungsgemeinschaft

German Federal Ministry of Education and Research



Traditional treatments for breast cancer fail to address therapy-resistant cancer stem–like cells that have been characterized by changes in epigenetic regulators such as the lysine demethylase KDM4. Here, we describe an orally available, selective and potent KDM4 inhibitor (QC6352) with unique preclinical characteristics. To assess the antitumor properties of QC6352, we established a method to isolate and propagate breast cancer stem–like cells (BCSC) from individual triple-negative tumors resected from patients after neoadjuvant chemotherapy. Limiting-dilution orthotopic xenografts of these BCSCs regenerated original patient tumor histology and gene expression. QC6352 blocked BCSC proliferation, sphere formation, and xenograft tumor formation. QC6352 also abrogated expression of EGFR, which drives the growth of therapy-resistant triple-negative breast cancer cells. Our findings validate a unique BCSC culture system for drug screening and offer preclinical proof of concept for KDM4 inhibition as a new strategy to treat triple-negative breast cancer. Cancer Res; 77(21); 5900–12. ©2017 AACR.

Usage metrics

    Cancer Research